← Back to Search

PDE4 Inhibitor

PDE4 Inhibitor for Skin Conditions

Phase 2
Recruiting
Led By Benjamin Ungar, MD
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child
Diagnosis of SD and baseline IGA ≥ 3 with facial involvement OR Diagnosis of PPR, baseline IGA ≥ 3, and baseline inflammatory lesion count ≥ 12
Must not have
Use of systemic biologic immunosuppressive medications within 12 weeks of baseline
Subject has previously received treatment with oral or topical PDE4 inhibitors
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 8 weeks, 12 weeks

Summary

This trial will test a new ointment to treat skin conditions Seborrheic Dermatitis and Papulopustular Rosacea in adults. Subjects will apply ointment once daily for 8 weeks and be monitored for improvement.

Who is the study for?
Adults over 18 with moderate-to-severe Seborrheic Dermatitis (SD) or Papulopustular Rosacea (PPR), who have specific severity scores and agree to avoid other treatments during the study. Participants must use effective contraception, be in good health, and not have used certain medications recently.
What is being tested?
The trial is testing PF-07038124 ointment against a placebo for SD and PPR. It's double-blind, meaning neither participants nor researchers know who gets the real treatment. Subjects apply it daily for 8 weeks with follow-ups at weeks 4, 8, and 12.
What are the potential side effects?
While specific side effects of PF-07038124 are not listed here, common side effects of topical treatments may include skin irritation, redness, itching or burning sensation at the application site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am willing to use birth control to prevent pregnancy or fathering a child.
Select...
My skin condition is severe with significant facial involvement.
Select...
I am 18 years or older and have signed the consent form.
Select...
I agree to stop all other treatments for my skin condition during the study, except for the study drug.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I haven't taken any immune-weakening drugs in the last 12 weeks.
Select...
I have taken PDE4 inhibitors before.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 8 weeks, 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 8 weeks, 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Subjects reaching Investigator's Global Assessment (IGA) success - Seborrheic dermatitis (SD)
Percent change in lesion count Papulopustular Rosacea (PPR)
Secondary study objectives
Change in Clinical Erythema - PPR
Change in IGA Score - SD and PPR
Change in Lesion count - PPR
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PF-07038124Experimental Treatment1 Intervention
PF-07038124 0.02% ointment once daily for 8 weeks
Group II: PlaceboPlacebo Group1 Intervention
Placebo Ointment

Find a Location

Who is running the clinical trial?

PfizerIndustry Sponsor
4,660 Previous Clinical Trials
17,877,261 Total Patients Enrolled
Icahn School of Medicine at Mount SinaiLead Sponsor
904 Previous Clinical Trials
541,739 Total Patients Enrolled
Benjamin Ungar, MDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai
1 Previous Clinical Trials
45 Total Patients Enrolled
~7 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top